Glenmark Pharmaceuticals Launches Epinephrine Injection in USA
Filing Summary
Glenmark Pharmaceuticals Inc., USA has launched the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. This product is bioequivalent and therapeutically equivalent to the reference drug by BPI Labs, LLC. According to IQVIA sales data, the market for this product achieved annual sales of approximately USD 68 million for the 12-month period ending October 2025. Glenmark Pharmaceuticals Ltd. is a global pharmaceutical company with a focus on respiratory, dermatology, and oncology therapeutic areas.
Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of its Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) by BPI Labs, LLC, under NDA 205029.
According to IQVIA sales data, the market for Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) reached annual sales of approximately USD 68 million for the 12-month period ending October 2025. This market includes both brand and all available therapeutic equivalents. Glenmark’s product is approved for the indications listed in its approved label.
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company with a presence in branded, generics, and OTC segments. The company focuses on therapeutic areas such as respiratory, dermatology, and oncology. It operates 11 manufacturing facilities across four continents and has a presence in over 80 countries. Glenmark’s Green House Gas emission reduction targets were approved by the Science Based Target initiative in 2023, making it the second pharmaceutical company in India to achieve this.